Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D)

To present the pre-specified analyses of >5-years follow-up of the Phase III ALTTO trial.8381 patients with stage I-III HER2 positive breast cancer randomised to chemotherapy plus 1-year of trastuzumab (T), oral lapatinib (L; no longer evaluated), trastuzumab followed by lapatinib (T→L), and lapatinib + trastuzumab (L+T). The primary endpoint was disease-free survival (DFS). A secondary analysis examined DFS treatment effects by hormone receptor...